Want to see GB:VAL full AI Analyst Report?
Top Page
ValiRx plc
(LSE:VAL)
Select Model
Select Model
Rating:39Underperform
Price Target:
0.12 p
▼(-26.25% Downside)
Action:Downgraded
Date:09/28/26
The score is primarily constrained by weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn that is eroding equity) and very bearish technicals (below all major moving averages with negative MACD). Valuation provides only limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Very low leverage
Minimal debt limits interest obligations and reduces leverage-related financial risk. This gives ValiRx greater flexibility than a highly indebted developer when allocating scarce capital, although its ability to fund operations remains constrained by continuing cash losses.
Negative Factors
Declining and minimal revenue
Revenue remains extremely small relative to the company’s operating cost base and declined materially year over year. This indicates that commercial or partnered income is not yet providing a durable funding engine, leaving ValiRx dependent on future asset progress or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt limits interest obligations and reduces leverage-related financial risk. This gives ValiRx greater flexibility than a highly indebted developer when allocating scarce capital, although its ability to fund operations remains constrained by continuing cash losses.
Read all positive factors
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.65M
Dividend YieldN/A
Average Volume (3M)4.35M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-34.36%
EPS Growth57.45%
CountryUK
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume5,014,913
30 Day Avg. Volume4,351,778
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to trea...
ValiRx plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.67K | 31.37K | 49.77K | 9.60K | 0.00 | 0.00 |
| Gross Profit | -112.46K | -6.25K | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -1.60M | -2.18M | -1.86M | -2.04M | -2.37M | -1.45M |
| Net Income | -2.14M | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | ||||||
| Total Assets | 2.77M | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 970.56K | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 0.00 | 1.40K | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 120.82K | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 3.13M | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.36M | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.36M | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -2.59K | -13.58K | -38.16K | -306.18K | 0.00 | 0.00 |
| Financing Cash Flow | 1.81M | 759.35K | 3.00M | 1.12M | 2.26M | 7.34K |
ValiRx plc Technical Analysis
Neutral
0.16
Price Trends
0.15
Negative
0.16
Negative
0.25
Negative
Market Momentum
>-0.01
Positive
51.74
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Neutral. The current price of 0.16 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.15, and below the 200-day MA of 0.25, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 51.74 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:VAL.
ValiRx plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £115.16M | -17.74 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £42.62M | -8.52 | -284.01% | ― | ― | -105.65% | |
44 Neutral | £20.31M | -2.60 | -559.87% | 17.86% | ― | 5.62% | |
44 Neutral | £32.59M | -2.16 | -2807.75% | ― | ― | 18.57% | |
42 Neutral | £4.78M | -1.80 | -93.92% | ― | ― | 55.56% | |
39 Underperform | £1.65M | -0.71 | -71.49% | ― | -34.36% | 57.45% |
* Healthcare Sector Average
GB:VAL
ValiRx plc
0.14
-0.39
-74.29%
GB:TCF
Evgen Pharma
0.18
-0.04
-18.18%
GB:IMM
ImmuPharma
3.25
-9.75
-75.00%
GB:SAR
Sareum Holdings
31.00
5.00
19.23%
GB:SCLP
Scancell Holdings
9.40
-0.35
-3.59%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
477.00
-683.00
-58.88%
ValiRx plc Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
ValiRx tightens operations and bolsters cash as it refocuses pipeline and portfolio
Positive
Sep 15, 2026
ValiRx has tightened its operations in the first half of 2026, fully implementing a lean strategy that cut administrative costs and delivered additional annual savings, while refocusing Inaphaea BioLabs on supporting the company’s own pipeli...
Business Operations and StrategyRegulatory Filings and Compliance
ValiRx bolsters Cytolytix cancer IP with new European patent and delivery platform filing
Positive
Aug 10, 2026
ValiRx plc has strengthened the intellectual property position of its majority-owned subsidiary Cytolytix, with the European Patent Office indicating its intention to grant a second European patent covering polyleucine-based anti-cancer peptides l...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
ValiRx AGM Backs Strategy as Board Changes and Large Warrant Issue Follow
Positive
Jul 17, 2026
ValiRx plc announced that all resolutions were approved at its Annual General Meeting, reinforcing shareholder support for the current strategy in oncology and women’s health. The company also confirmed the departure of non-executive directo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.